✦ LIBER ✦

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

✍ Scribed by Kenneth B. Gordon; Kim A. Papp; Richard G. Langley; Vincent Ho; Alexa B. Kimball; Cynthia Guzzo; Newman Yeilding; Philippe O. Szapary; Steven Fakharzadeh; Shu Li; Ming-Chun Hsu; Kristian Reich

Book ID: 116588142
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 422 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.06.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The ustekinumab safety experience in pat

The ustekinumab safety experience in patients with moderate to severe psoriasis: Results from pooled analyses of phase II and phase III clinical trial data

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Long-term safety experience of ustekinum

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

✍ Mark Lebwohl; Craig Leonardi; Christopher E.M. Griffiths; Jörg C. Prinz; Philipp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Cardiovascular safety of ustekinumab in

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

✍ K. Reich; R.G. Langley; M. Lebwohl; P. Szapary; C. Guzzo; N. Yeilding; S. Li; M- 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB

Efficacy and safety of ustekinumab in Ja

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

✍ Atsuyuki IGARASHI; Takeshi KATO; Mai KATO; Michael SONG; Hidemi NAKAGAWA; THE JA 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

Underdiagnosis and undertreatment of car

Underdiagnosis and undertreatment of cardiovascular risk factors among patients with moderate to severe psoriasis: Results from phase III ustekinumab clinical trials

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Update on the cardiovascular safety of u

Update on the cardiovascular safety of ustekinumab in pooled phase II and III psoriasis clinical trials with up to 4 years of follow-up

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB